http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20120807:nBw075733a
   CONCORD, Calif.--(Business Wire)--Cerus Corporation (NASDAQ: CERS) announced today that Hemakim, Cerus`distributor for Turkey, has signed an agreement with the Florence NightingaleHospital, a leading medical center in Turkey, to supply the INTERCEPT BloodSystem for platelets and plasma. "With the adoption of the INTERCEPT Blood System, we know we are doingeverything in our power to provide patients with safe and effective bloodproducts, consistent with our mission to use innovative products to continuouslyimprove patient care," said Dr. Hulya Bilgen, associate professor and directorof the Florence Nightingale Transfusion Center. "We strive to provide ourpatients and their families with the best the world can offer, with service froma qualified and experienced clinical staff." "We are extremely proud that the INTERCEPT system meets Florence NightingaleHospital`s demanding standards for healthcare technologies, and we share theHospital`s passion for patient safety," said Caspar Hogeboom, president of CerusEurope. "Including Turkey, customers in 18 countries have chosen the INTERCEPTBlood System to protect patients from transfusion-transmitted diseases." The Florence Nightingale Hospital Group, based in Istanbul, Turkey, offerspatient-centered and specialized healthcare by integrating education, researchand technology with clinical care. The group was founded in 1989, under the bodyof Turkish Cardiology Foundation, as the first cardiovascular disease hospitalin the region. Today, with four general hospitals, a medical center, a teachinghospital, a clinical research center and a Hi-Tech hospital, the FlorenceNightingale Hospital Group is one of the largest and most reputed hospitals inEurope and the Middle East. ABOUT CERUSCerus Corporation is a biomedical products company focused on commercializingthe INTERCEPT Blood System to enhance blood safety. The INTERCEPT system isdesigned to reduce the risk of transfusion-transmitted diseases by inactivatinga broad range of pathogens such as viruses, bacteria and parasites that may bepresent in donated blood. The nucleic acid targeting mechanism of action enablesINTERCEPT treatment to inactivate established transfusion threats, such ashepatitis B and C, HIV, West Nile virus and bacteria, and is designed toinactivate emerging pathogens such as influenza, malaria and dengue. Ceruscurrently markets and sells the INTERCEPT Blood System for both platelets andplasma in Europe, the Commonwealth of Independent States, the Middle East andselected countries in other regions around the world. The INTERCEPT red bloodcell system is in clinical development. See 
  http://www.cerus.com
  for moreinformation. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.  Cerus CorporationLainie Corten, 925-288-6319Sr Director, Global Marketing & Investor Relations Copyright Business Wire 2012